Lytix Biopharma AS (OSL:LYTIX) Change In Inventory: kr0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:LYTIX Lytix Biopharma AS OSL:LYTIX
29 GF Score
Price kr8.40
GF Value kr0.17
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Lytix Biopharma AS Change In Inventory?

Lytix Biopharma AS OSL:LYTIX +1.20% 29 Change In Inventory is kr0.00 Mil as of Jun. 2026. GuruFocus rates OSL:LYTIX with a GF Score™ of 29/100 and a GF Value™ of kr0.17 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Lytix Biopharma AS's change in inventory for the quarter that ended in Jun. 2026 was kr0.00 Mil. It means Lytix Biopharma AS's inventory stayed the same from Mar. 2026 to Jun. 2026 .

Lytix Biopharma AS's change in inventory for the fiscal year that ended in Dec. 2025 was kr0.00 Mil. It means Lytix Biopharma AS's inventory stayed the same from Dec. 2024 to Dec. 2025 .

Lytix Biopharma AS's Total Inventories for the quarter that ended in Jun. 2026 was kr0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Lytix Biopharma AS  (OSL:LYTIX) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Lytix Biopharma AS's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=0/0*365 / 4
=N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Lytix Biopharma AS's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=0 / 0
=N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Lytix Biopharma AS's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lytix Biopharma AS Change In Inventory Related Terms

Lytix Biopharma AS Change In Inventory Historical Data

* Premium members only.

The historical data trend for Lytix Biopharma AS's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lytix Biopharma AS Change In Inventory Chart

Lytix Biopharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Inventory
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Lytix Biopharma AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSL:LYTIX
29GF Score
Lytix Biopharma AS OSL:LYTIX
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lytix Biopharma AS Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of kr0.00 Mil mean?
Lytix Biopharma AS (OSL:LYTIX) has a Change In Inventory of kr0.00 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Lytix Biopharma AS and its competitors.
Is Lytix Biopharma AS's Change In Inventory too high?
Lytix Biopharma AS's current Change In Inventory is kr0.00 Mil. Overall, Lytix Biopharma AS has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lytix Biopharma AS's Change In Inventory compare to VRTX and REGN?
Lytix Biopharma AS's Change In Inventory of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Lytix Biopharma AS and its competitors. Lytix Biopharma AS's current Change In Inventory is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lytix Biopharma AS stock overvalued right now?
Based on GuruFocus' analysis, Lytix Biopharma AS (OSL:LYTIX) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.17, compared to a current price of kr8.40 — trading 4841.2% above its estimated fair value. The current Change In Inventory is kr0.00 Mil. Lytix Biopharma AS's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Lytix Biopharma AS (OSL:LYTIX), the current Change In Inventory is kr0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lytix Biopharma AS (OSL:LYTIX) Overvalued in 2026?

Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued. The current stock price of kr8.40 is trading 4841.2% above its estimated GF Value™ of kr0.17. GuruFocus considers Lytix Biopharma AS to be Significantly Overvalued.

Key valuation signals for OSL:LYTIX:

  • Change In Inventory: kr0.00 Mil
  • GF Value™: kr0.17 vs. price of kr8.40 (4841.2% above fair value)
  • GF Score™: 29/100 with 1 warning sign

No single metric tells the full story. See the OSL:LYTIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lytix Biopharma AS Business Description

Address Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
29GF Score

Get the complete analysis for OSL:LYTIX

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr8.40
Price
kr0.17
GF Value